Validation of isolated metabolites from drug metabolism studies as analytical standards by quantitative NMR

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 433-440

  Walker, Gregory S ^a   Ryder, Tim F ^a   Sharma, Raman ^a   Smith, Evan B ^a   Freund, Amy ^b  

^a PFIZER INC   (United States)

^b BRUKER BIOSPIN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROBENZYLGLUTATHIONE; BUSPIRONE; CAFFEINE; DELAVIRDINE; DRUG METABOLITE; ENALAPRIL; GLUTATHIONE DERIVATIVE; MALEIC ACID; MELOXICAM; OMEPRAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; ARTIFICIAL SIGNAL INSERTION FOR CALCULATION OF CONCENTRATION OBSERVED; DRUG METABOLISM; MATHEMATICAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; STANDARD; VALIDATION PROCESS;

CALIBRATION; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOKINETICS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79951931440     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036343     Document Type: Article

References (24)

1. Akoka S, Barantin L, and Trierweiler M (1999) Concentration measurement by proton NMR using the ERETIC method. Anal Chem 71:2554-2557. (Pubitemid 29307625)
2. Dalisay DS and Molinski TF (2009) NMR quantitation of natural products at the nanomole scale. J Nat Prod 72:739-744.
3. Dear GJ, Roberts AD, Beaumont C, and North SE (2008) Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 876:182-190.
4. 1H NMR spectroscopy, HPLC-NMR/MS and UPLC-MS. Mol BioSyst 5:180-190.
5. Espina R, Yu L, Wang J, Tong Z, Vashishtha S, Talaat R, Scatina J, and Mutlib A (2009) Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem Res Toxicol 22:299-310.
6. Görög S (2008) Drug safety, drug quality, drug analysis. J Pharm Biomed Anal 48:247-253.
7. Kalgutkar AS (2008) Role of bioactivation in idiosyncratic drug toxicity: structure-toxicity relationships. Biotechnol Pharm Aspects 9:27-55.
8. Kaye B, Rance DJ, and Waring L (1985) Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15:237-242. (Pubitemid 15050132)
9. Kuo MS, Shilliday FB, and Yurek DA (2001) Chromatographic analysis of compounds of pharmaceutical interest. J Chromatogr Sci 39:513-520. (Pubitemid 34984080)
10. Malz F and Jancke H (2005) Validation of quantitative NMR. J Pharm Biomed Anal 38:813-823. (Pubitemid 41115787)
11. Molinier V, Fenet B, Fitremann J, Bouchu A, and Queneau Y (2006) Concentration measurements of sucrose and sugar surfactants solutions by using the 1H NMR ERETIC method. Carbohydr Res 341:1890-1895. (Pubitemid 43866050)
12. Nedderman AN (2009) Metabolites in safety testing: metabolite identification strategies in discovery and development. Biopharm Drug Dispos 30:153-162.
13. 1H NMR: development and potential of a method for natural products analysis. J Nat Prod 68:133-149.
14. Pauli GF, Jaki BU, and Lankin DC (2007) A routine experimental protocol for qHNMR illustrated with Taxol. J Nat Prod 70:589-595. (Pubitemid 46797861)
15. Pauli GF, Jaki BU, Lankin DC, Walter JA, and Burton IW (2008) Quantitative NMR of bioactive natural products, in Bioactive Natural Products: Detection, Isolation, and Structural Determination, 2nd ed (Colegate SM and Molyneux RJ eds) pp 113-141, CRC Press, Boca Raton, FL.
16. Prakash C, Shaffer CL, and Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340-369. (Pubitemid 46750374)
17. U.S. Food and Drug Administration (2008) Guidance for industry: Safety Testing of Drug Metabolites, Center for Drug Evaluation and Research, Silver Spring, MD.
18. Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, and Scatina J (2009) Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem Res Toxicol 22:311-322.
19. Wang Y, Huang S, and Reily M (2009) Development of the use of carbon-13 satellites of NMR solvents as internal standards for quantitative NMR of small molecule analytes at the microgram scale and applications in drug discovery, in Abstracts of the 36th Northeast Regional Meeting of the American Chemical Society; 2009 October 7-10; Hartford, CT. NERM-171, American Chemical Society, Washington, DC.
20. Weishaar RE, Quade M, Boyd D, Schenden J, Marks S, and Kaplan HR (1983) The effect of several "new and novel" cardiotonic agents on key subcellular processes involved in the regulation of myocardial contractility: implications for mechanism of action. Drug Dev Res 3:517-534. (Pubitemid 14221034)
21. Williams RL, 2000-2005 Reference Standards Committee of the USP Council of Experts and Its Advisory Panel, and USP Staff and Consultant (2006) Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities. J Pharm Biomed Anal 40:3-15.
22. Xiao C, Liu H, Dai H, Tseng L, Spraul M, Wang Y, and Tang H (2009) Efficient identification and structural elucidation of metabolites using HPLC-DAD-SPECryoNMR-MS method. Bopuxue Zazhi 26:1-16.
23. Yurek DA, Branch DL, and Kuo MS (2002) Development of a system to evaluate compound identity, purity, and concentration in a single experiment and its application in quality assessment of combinatorial libraries and screening hits. J Comb Chem 4:138-148.
24. Ziarelli F, Viel S, Caldarelli S, Sobieski DN, and Augustine MP (2008) General implementation of the ERETIC method for pulsed field gradient probe heads. J Magn Reson 194:307-312.